Publications in OpenAlex of which a co-author is affiliated to this organization
All publications | By field | By subfield
All publications [Next]
| Title | DOI |
|---|---|
| https://doi.org/10.1161/circulationaha.122.063372 | Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor |
| https://doi.org/10.1002/cpdd.647 | Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX‐02, a Potential Treatment for Genetic Disorders Caused by Nonsense Mutations, in Healthy Volunteers |
| https://doi.org/10.1016/j.jobe.2022.104436 | Revamping corrosion damaged reinforced concrete balconies: Life cycle assessment and life cycle cost of life-extending repair methods |
| https://doi.org/10.1002/jcph.1638 | Pharmacokinetics and Pharmacodynamics of Garetosmab (Anti‐Activin A): Results From a First‐in‐Human Phase 1 Study |
| https://doi.org/10.1016/j.biologicals.2018.02.002 | Human challenge trials in vaccine development, Rockville, MD, USA, September 28–30, 2017 |
| https://doi.org/10.5414/cpp38387 | Nitazoxanide: pharmacokinetics and metabolism in man |
| https://doi.org/10.1080/13543784.2016.1255724 | Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects |
| https://doi.org/10.1016/j.trd.2010.07.001 | Transportation Risk ANalysis tool for hazardous Substances (TRANS) – A user-friendly, semi-quantitative multi-mode hazmat transport route safety risk estimation methodology for Flanders |
| https://doi.org/10.4155/bio.12.18 | Recommendations on The Interpretation of The New European Medicines Agency Guideline on Bioanalytical Method Validation By Global Cro Council For Bioanalysis (Gcc) |
| https://doi.org/10.1111/cts.12578 | Evaluation of Pharmacokinetics and Pharmacodynamics of |
| https://doi.org/10.1007/s00228-008-0591-6 | Clinical pharmacology of exogenously administered alkaline phosphatase |
| https://doi.org/10.1002/cpdd.914 | A Randomized, Double‐Blind, Placebo‐Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX‐02 in Healthy Subjects |
| https://doi.org/10.1186/s12985-015-0240-5 | Characterisation of a wild-type influenza (A/H1N1) virus strain as an experimental challenge agent in humans |
| https://doi.org/10.4155/bio.12.192 | Recommendations on Bioanalytical Method Stability Implications of Co-Administered And Co-Formulated Drugs By Global Cro Council For Bioanalysis (Gcc) |
| https://doi.org/10.4155/bio.11.242 | Conference Report: The 3rd Global CRO Council for Bioanalysis at The International Reid Bioanalytical Forum |
| https://doi.org/10.1016/j.ebiom.2021.103810 | Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study |
| https://doi.org/10.1182/blood.v128.22.2032.2032 | First-in-Human Phase 1a Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Noncovalent Bruton Tyrosine Kinase (BTK) Inhibitor SNS-062 in Healthy Subjects |
| https://doi.org/10.1002/hup.2569 | A phase I, randomized, proof‐of‐clinical‐mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral |
| https://doi.org/10.3390/cancers15153867 | Mixed-Method Systematic Review and Meta-Analysis of Shared Decision-Making Tools for Cancer Screening |
| https://doi.org/10.1161/circ.130.suppl_2.18403 | Abstract 18403: Effect of Dabigatran on the Ability to Generate Fibrin at a Wound site and its Reversal by Idarucizumab, the Antidote to Dabigatran, in Healthy Volunteers: An Exploratory Marker of Blood Loss |
| https://doi.org/10.1111/bcp.13269 | Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies |
| https://doi.org/10.1016/s2666-5247(24)00024-7 | Assessment of CD8+ T-cell mediated immunity in an influenza A(H3N2) human challenge model in Belgium: a single centre, randomised, double-blind phase 2 study |
| https://doi.org/10.1111/cts.13724 | LTA4H inhibitor LYS006: Clinical PK/PD and safety in a randomized phase I clinical trial |
| https://doi.org/10.1111/cts.70331 | Safety and Pharmacokinetics of |
| https://doi.org/10.1177/0734242x251345326 | Polyfluoroalkyl substances in dedicated hazardous waste incinerators: Framework and industrial scale experimental estimation of destruction and removal efficiency |
| https://doi.org/10.3389/fphar.2025.1540948 | Healthy participant engagement in early clinical trials: results from the European EUFEMED survey |
| https://doi.org/10.4155/bio.12.172 | Recommendations on Isr in Multi Analyte Assays, Qa/Bioanalytical Consultants And Gcp By Global Cro Council For Bioanalysis (Gcc) |
| https://doi.org/10.1002/cpdd.244 | Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo‐Controlled Studies in Healthy Volunteers |
| https://doi.org/10.1111/cts.13762 | Pharmacokinetics and pharmacodynamics of mibavademab (a leptin receptor agonist): Results from a first‐in‐human phase I study |
| https://doi.org/10.1016/j.jalz.2012.05.500 | P1‐221: Safety and pharmacokinetics of the novel BACE inhibitor MK‐8931 in healthy subjects following single‐ and Multiple‐Dose administration |
| https://doi.org/10.2165/00003088-200948060-00001 | Systemic Exposure and Implications for Lung Deposition with an Extra-Fine Hydrofluoroalkane Beclometasone Dipropionate/Formoterol Fixed Combination |
| https://doi.org/10.4161/hv.19454 | Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events |
| https://doi.org/10.1002/for.2457 | The importance of time‐varying volatility and country interactions in forecasting economic activity |
| https://doi.org/10.1007/s00228-003-0714-z | Effect of the novel anxiolytic drug deramciclane on cytochrome P 450 2D6 activity as measured by desipramine pharmacokinetics |
| https://doi.org/10.1016/b978-0-12-820472-6.00017-7 | Systems Pharmacology: Enabling Multidimensional Therapeutics |
| https://doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a4528 | Pharmacokinetic/Pharmacodynamic Interactions Between Extrafine Beclomethasone Dipropionate and Formoterol Fumarate Components of a Fixed-Dose Combination for Asthma and COPD |
| https://doi.org/10.1183/13993003.congress-2020.3242 | Trends in primary outcome parameters for respiratory trials |
| https://doi.org/10.1016/j.toxac.2025.01.031 | Ethylated phosphorylcholine – a new marker for ethanol consumption: A proof of concept |
| https://doi.org/10.22541/au.175195283.31505268/v1 | Why do healthy volunteers participate in clinical trials? |
| https://doi.org/10.12688/verixiv.994.1 | Mass Balance, Pharmacokinetics, Metabolism and Excretion of Radiolabelled Acoziborole, a Potential Novel Treatment for Human African Trypanosomiasis, following Single Microtracer Oral Dose to Humans |
| https://doi.org/10.1128/aac.00580-25 | Mass balance, pharmacokinetics, metabolism, and excretion of radiolabeled acoziborole, a potential novel treatment for human African trypanosomiasis, following single microtracer oral dose to humans |
| https://doi.org/10.1117/12.3072706 | High-NA EUV optical proximity correction modeling flow: from data preparation to model validation |
| https://doi.org/10.1002/bcp.70328 | Safety, tolerability and pharmacokinetics of DNDI‐6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants |
| https://doi.org/10.1007/s40261-025-01508-w | Unexpected Clinical Drug-Drug Interaction of Fexinidazole on Midazolam Pharmacokinetics: Insights into Underlying Mechanisms from Clinical Phase I Study Results and Supporting In Vivo/Vitro Evidence |
| https://doi.org/10.1002/bcp.70499 | Why do healthy volunteers participate in clinical trials? |